Want to see SDZNY full AI Analyst Report?
SDZNY Stock Chart & Stats
$77.82
-$0.10(-0.12%)
At close: 4:00 PM EDT
$77.82
-$0.10(-0.12%)
Day’s Range― - ―
52-Week Range$56.02 - $93.65
Previous CloseN/A
Volume33.41K
Average Volume (3M)5.06K
Market Cap
$35.77B
Enterprise Value$35.89K
Total Cash (Recent Filing)$1.74B
Total Debt (Recent Filing)$5.68B
Price to Earnings (P/E)38.2
Beta0.64
Next Earnings
Mar 17, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.26%
Share Statistics
EPS (TTM)2.12
Shares Outstanding440,000,000
10 Day Avg. Volume10,563
30 Day Avg. Volume5,063
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)3.34
Price to Sales (P/S)2.81
P/FCF Ratio38.74
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Biosimilars Growth And PipelineHigh single‑digit and double‑digit biosimilar growth, a record 33% sales mix and a 36‑asset pipeline create a durable, higher‑margin growth vector. Combined with successful launches and manufacturing scale, this reduces reliance on low‑margin generics and supports sustained revenue diversification.
Margin Resilience And ExpansionSustained mid‑to‑high‑40% gross margins and recent ~90bp core EBITDA margin expansion indicate structural operating leverage. This margin durability supports reinvestment and debt service during an investment cycle and cushions earnings against generic price erosion over the medium term.
Manageable Leverage And Improving Cash GenerationNet‑debt/EBITDA (~1.4x), ample liquidity and investment‑grade ratings together with H1 free cash flow (~$503m) provide financial flexibility. This balance‑sheet capacity supports elevated CapEx and settlement phasing while limiting refinancing risk and enabling continued strategic investments.
Bears Say
Structural Pricing ErosionA mid‑single‑digit expected price decline reflects enduring pricing pressure in core generics markets. Over time this structural erosion can compress unit economics, force higher volume to sustain revenues, and limit margin upside unless biosimilar mix or unit market share materially offsets losses.
Elevated, Peak CapEx CycleA near‑term CapEx peak (~$1.1bn) funds capacity and R&D but intensifies cash conversion demands. Until these investments yield steady incremental returns, free cash flow and discretionary spending may be constrained, raising execution risk if revenue or margin ramps disappoint.
Multi‑year Legal And Settlement ObligationsStructured settlement payments and residual opt‑out claims create ongoing cash obligations and legal uncertainty across multiple years. These liabilities reduce net cash available for strategic initiatives, add forecasting complexity, and could prompt further provisions if additional claims arise.
Sandoz Group Ltd Sponsored ADR News
SDZNY FAQ
What was Sandoz Group Ltd Sponsored ADR’s price range in the past 12 months?
Sandoz Group Ltd Sponsored ADR lowest stock price was $56.02 and its highest was $93.64 in the past 12 months.
What is Sandoz Group Ltd Sponsored ADR’s market cap?
Sandoz Group Ltd Sponsored ADR’s market cap is $35.77B.
When is Sandoz Group Ltd Sponsored ADR’s upcoming earnings report date?
Sandoz Group Ltd Sponsored ADR’s upcoming earnings report date is Mar 17, 2027 which is in 223 days.
How were Sandoz Group Ltd Sponsored ADR’s earnings last quarter?
Currently, no data Available
Is Sandoz Group Ltd Sponsored ADR overvalued?
According to Wall Street analysts Sandoz Group Ltd Sponsored ADR’s price is currently Overvalued.
Does Sandoz Group Ltd Sponsored ADR pay dividends?
Sandoz Group Ltd Sponsored ADR pays a Annually dividend of $1.021 which represents an annual dividend yield of 1.26%. See more information on Sandoz Group Ltd Sponsored ADR dividends here
What is Sandoz Group Ltd Sponsored ADR’s EPS estimate?
Sandoz Group Ltd Sponsored ADR’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sandoz Group Ltd Sponsored ADR have?
Sandoz Group Ltd Sponsored ADR has 440,000,000 shares outstanding.
What happened to Sandoz Group Ltd Sponsored ADR’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Sandoz Group Ltd Sponsored ADR?
Currently, no hedge funds are holding shares in SDZNY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sandoz Group Ltd Sponsored ADR Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Neutral
SDZNY Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 55.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
29.81%
12-Months-Change
Fundamentals
Return on Equity
1.26%
Trailing 12-Months
Asset Growth
10.67%
Trailing 12-Months
Company Description
Sandoz Group Ltd Sponsored ADR
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. Sandoz Group AG was founded in 1886 and is headquartered in Basel, Switzerland.
SDZNY Company Deck
SDZNY Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a broadly positive performance story: strong biosimilar-led top-line growth, margin expansion, resilient cash generation despite a significant CapEx cycle, an enlarged 36-asset biosimilar pipeline, major product launches with leading market shares, and strategic investments (Ljubljana center) that support medium-term growth. Near-term challenges include increased pricing erosion (now expected mid-single-digit), temporary generics headwinds (notably in Q1 and in some international markets), short-term tender/pricing disruption in Germany, elevated one-off and settlement-related cash outflows, and a heavier CapEx profile in 2026. Management reaffirmed 2026 guidance and emphasized confidence in 2027–2028 growth driven by upcoming launches and the multisource GLP-1 strategy. On balance, the positives around revenue momentum, profitability improvement, pipeline breadth, and strong commercial execution outweigh the near-term operational and pricing headwinds.View all SDZNY earnings summariesTechnical Analysis
Corcept Therapeutics
―
SCYNEXIS
―
Kiniksa Pharmaceuticals
―
Liquidia Technologies
―
Biofrontera
―
Ownership Overview
―
Insiders
0.19% Mutual Funds
0.03% Other Institutional Investors
99.67% Public Companies and
Individual Investors